Page 263 - Programme book for The International Liver Congress 2015, EASL ILC 2015
P. 263
P0821 ARE EXTENDED DURATIONS AND/OR RIBAVIRIN USEFUL ePOSTERS
P0822 FOR GENOTYPE 1 (G1) CIRRHOTIC PATIENTS WHO
RECEIVE DAAS COMBINATION ? A META-ANALYSIS OF
P0823 RANDOMIZED CONTROLLED TRIALS (RCTS)
P0824 Vincent Di Martino*, Carine Richou, Jean-Paul Cervoni, Delphine Weil,
P0825 Claire Vanlemmens, Thierry Thévenot, France
P0826
SAFETY AND EFFICACY OF SOFOSBUVIR CONTAINING
REGIMENS FOR HEPATITIS C: COMMUNITY TREATMENT
OF A REAL WORLD POPULATION WITH ADVANCED LIVER
FIBROSIS
Denis Ouzan*, Thierry Fontanges, Guillaume Pénaranda,
Patrick Delasalle, Michel Antoni, Solange Bresson-Hadni,
Patricia Cerdan, Sylvain Beorchia, Pierre Toulemonde, Nathalie Boyer,
Corinne Castelnau, Jean-Paul Jacques, Baesjou Serge, Corinne Bonny,
Samy Boussoukouya, Hélène Joly, Bertrand Hanslik, France
PHARMACOKINETICS OF PARITAPREVIR, OMBITASVIR,
RITONAVIR AND RIBAVIRIN IN SUBJECTS WITH HCV
GENOTYPE 4 INFECTION
Dörthe Eckert*, Tianli Wang, Sven Mensing, Amit Khatri,
Sandeep Dutta, Rajeev Menon, Germany
A PHASE 1 STUDY TO EVALUATE THE INTERACTION
OF HCV NS5B INHIBITOR MK-3682 WITH HCV NS3/4A
PROTEASE INHIBITOR MK-5172 AND HCV NS5A INHIBITOR
MK-8408 IN HEALTHY SUBJECTS
Xiao-Jian Zhou, Eric Sicard, Jie Chen, Dodie Frank, Wei Gao,
Matthew L. Rizk, Elizabeth G. Rhee*, Joan R. Butterton, John Sullivan-
Bolyai, The United States
VARYING EFFICACY OF SOFOSBUVIR TREATMENT
REGIMENS IN REAL LIFE SETTINGS
Emmanuelle Huchet*, Chrissi Galanakis, Benoit Trottier, Marc Poliquin,
Stephane Lavoie, Danièle Longpré, Sylvie Vézina, Caroline Bédard,
Nima Machouf, Réjean Thomas, Canada
EFFECTIVENESS OF SIMEPREVIR (SMV) - CONTAINING
REGIMENS AMONG PATIENTS WITH CHRONIC HEPATITIS
C VIRUS (HCV) IN VARIOUS US PRACTICE SETTINGS:
INTERIM ANALYSIS OF THE SONET STUDY
Imtaiz Alam*, Richard Manch, Susanna Naggie, Robert Reindollar,
Jihad Slim, Avi Prabhakar, Kris Lauwers, Cynthia Donovan,
Neeta Tandon, Jamie Forlenza, Kimberley Brown, The United States
Vienna, Austria • April 22–26, 2015 263
P0822 FOR GENOTYPE 1 (G1) CIRRHOTIC PATIENTS WHO
RECEIVE DAAS COMBINATION ? A META-ANALYSIS OF
P0823 RANDOMIZED CONTROLLED TRIALS (RCTS)
P0824 Vincent Di Martino*, Carine Richou, Jean-Paul Cervoni, Delphine Weil,
P0825 Claire Vanlemmens, Thierry Thévenot, France
P0826
SAFETY AND EFFICACY OF SOFOSBUVIR CONTAINING
REGIMENS FOR HEPATITIS C: COMMUNITY TREATMENT
OF A REAL WORLD POPULATION WITH ADVANCED LIVER
FIBROSIS
Denis Ouzan*, Thierry Fontanges, Guillaume Pénaranda,
Patrick Delasalle, Michel Antoni, Solange Bresson-Hadni,
Patricia Cerdan, Sylvain Beorchia, Pierre Toulemonde, Nathalie Boyer,
Corinne Castelnau, Jean-Paul Jacques, Baesjou Serge, Corinne Bonny,
Samy Boussoukouya, Hélène Joly, Bertrand Hanslik, France
PHARMACOKINETICS OF PARITAPREVIR, OMBITASVIR,
RITONAVIR AND RIBAVIRIN IN SUBJECTS WITH HCV
GENOTYPE 4 INFECTION
Dörthe Eckert*, Tianli Wang, Sven Mensing, Amit Khatri,
Sandeep Dutta, Rajeev Menon, Germany
A PHASE 1 STUDY TO EVALUATE THE INTERACTION
OF HCV NS5B INHIBITOR MK-3682 WITH HCV NS3/4A
PROTEASE INHIBITOR MK-5172 AND HCV NS5A INHIBITOR
MK-8408 IN HEALTHY SUBJECTS
Xiao-Jian Zhou, Eric Sicard, Jie Chen, Dodie Frank, Wei Gao,
Matthew L. Rizk, Elizabeth G. Rhee*, Joan R. Butterton, John Sullivan-
Bolyai, The United States
VARYING EFFICACY OF SOFOSBUVIR TREATMENT
REGIMENS IN REAL LIFE SETTINGS
Emmanuelle Huchet*, Chrissi Galanakis, Benoit Trottier, Marc Poliquin,
Stephane Lavoie, Danièle Longpré, Sylvie Vézina, Caroline Bédard,
Nima Machouf, Réjean Thomas, Canada
EFFECTIVENESS OF SIMEPREVIR (SMV) - CONTAINING
REGIMENS AMONG PATIENTS WITH CHRONIC HEPATITIS
C VIRUS (HCV) IN VARIOUS US PRACTICE SETTINGS:
INTERIM ANALYSIS OF THE SONET STUDY
Imtaiz Alam*, Richard Manch, Susanna Naggie, Robert Reindollar,
Jihad Slim, Avi Prabhakar, Kris Lauwers, Cynthia Donovan,
Neeta Tandon, Jamie Forlenza, Kimberley Brown, The United States
Vienna, Austria • April 22–26, 2015 263
